Vilanterol

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Vilanterol
Vilanterol.svg
Clinical data
License data
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)
  • US: ℞-only
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ECHA InfoCard 100.217.751 Edit this at Wikidata
Chemical and physical data
Formula C24H33Cl2NO5
Molar mass 486.43 g/mol
3D model (JSmol)

Vilanterol (INN, USAN) is an ultra-long-acting β2 adrenoreceptor agonist (ultra-LABA), which was approved in May 2013 in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD).[1]

Vilanterol is available in following combinations:

See also[edit]

  • Salmeterol — a long-acting β2 adrenoreceptor agonist (LABA) with a similar backbone.

References[edit]

  1. ^ "FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease". Retrieved 10 May 2013.